Dec 7, 2018
NCT03399799: Phase 1 - Talquetamab, a Humanized GPRC5D x CD3 Bis Ab - Ref MM - MonumenTAL-1
MonumenTAL-1 study A Phase 1, First-in-Human, Open-Label, Dose Escalation Study of Talquetamab, a Humanized GPRC5D x CD3 Bispecific...
715
Dec 6, 2018
NCT03464916: Phase 1: Study to Evaluate the Safety and Efficacy of Anti-CD38 CAR-T in RRMM
NCT03464916: Phase 1: Study to Evaluate the Safety and Efficacy of Anti-CD38 CAR-T in Relapsed or Refractory Multiple Myeloma Patients...
156
Dec 5, 2018
NCT03650491: Phase 1: A Study of FOR46 in Patients With Relapsed or Refractory Multiple Myeloma
NCT03650491: Phase 1: A Study of FOR46 in Patients With Relapsed or Refractory Multiple Myeloma (RRMM) This study will test the safety...
131
Dec 4, 2018
NCT03530683: Phase 1: A Trial of TTI-622 in Patients With Advanced Hem. Malignancies (TTI-622-01)
NCT03530683: Phase 1: A Trial of TTI-622 in Patients With Advanced Hematologic Malignancies (TTI-622-01) Sponsor Trillium Therapeutics...
537
Dec 4, 2018
NCT03702725: Phase 1: Study of Ibrutinib in Combination With Revlimid/Dexamethasone in RRMM Myeloma
NCT03702725: Phase 1: Study of Ibrutinib in Combination With Revlimid/Dexamethasone in Relapsed/Refractory Multiple Myeloma Study of...
48
Dec 2, 2018
NCT03424603: Phase 1: Study of STRO-001, an Anti-CD74 Antibody Drug Conjugate, B-Cell Malignancies
NCT03424603: Phase 1: Study of STRO-001, an Anti-CD74 Antibody Drug Conjugate, in Patients With Advanced B-Cell Malignancies Study of...
111
Dec 29, 2017
NCT03274219 : Phase 1 - bb21217 an Anti-BCMA CAR T Cell Drug Product, in RRMM - CRB-402
CRB-402 Study of bb21217 in Multiple Myeloma Relapsed Refractory Multiple Myeloma RRMM Study CRB-402 is a 2-part, non-randomized, open...
420
Dec 26, 2017
NCT03031730: Phase 1: Testing the Addition of KRT-232 (AMG 232) to Usual Chemotherapy RRMM Myeloma
NCT03031730: Phase 1: Testing the Addition of KRT-232 (AMG 232) to Usual Chemotherapy for Relapsed Multiple Myeloma Testing the Addition...
58
Dec 15, 2017
NCT03091257: Phase 1 - Dabrafenib and/or Trametinib in Patients With Relapsed Refractory Myeloma
Multiple Myeloma Research Consortium NCT03091257: Phase 1 - Dabrafenib and/or Trametinib in Patients With Relapsed and/or Refractory...
130
Dec 14, 2017
NCT03275103: Phase 1 - Dose-Escalation Study of Cevostamab in Participants With RRMM
NCT03275103: Phase 1 - Dose-Escalation Study of Cevostamab in Participants With Relapsed or Refractory Multiple Myeloma (R/R MM) A Phase...
355
Dec 13, 2017
NCT03318861: Phase 1: Study to Evaluate the Safety and Efficacy of KITE-585 in RRMM Multiple Myeloma
NCT03318861: Phase 1: Study to Evaluate the Safety and Efficacy of KITE-585 in Participants With Relapsed/Refractory Multiple Myeloma...
30
Dec 13, 2017
NCT03338972: Phase 1 - Autologous Anti-BCMA-CAR-expressing CD4+/CD8+ T-lymphocytes FCARH143 in RRMM
Immunotherapy With BCMA CAR-T Cells in Treating Patients With BCMA Positive Relapsed or Refractory Multiple Myeloma NCT03338972: Phase 1...
273
Dec 12, 2017
NCT03145181: Phase 1 - Teclistamab, Humanized BCMA*CD3 Bispecific Ab, in Relapsed Myeloma MajesTEC1
MajesTEC1 Dose Escalation Study of Teclistamab, a Humanized BCMA*CD3 Bispecific Antibody, in Participants With Relapsed or Refractory...
373
Dec 9, 2017
NCT03269136: Phase 1 -PF-06863135 As Single Agent & with Immunomodulatory Agents In relapsed Myeloma
NCT03269136 MAGNETISMM-1 RRMM NCT03269136: Phase 1 -PF-06863135 As Single Agent & with Immunomodulatory Agents In relapsed Myeloma To...
500
Dec 8, 2017
NCT03070327: Phase 1 - BCMA Targeted CAR T Cells With or Without Lenalidomide for Multiple Myeloma
A Phase I Trial of B-cell Maturation Antigen (BCMA) Targeted EGFRt/BCMA-41BBz Chimeric Antigen Receptor (CAR) Modified T Cells With or...
190
Dec 6, 2017
NCT03309111: Phase 1: ISB 1342, a CD38/CD3 Bispecific Antibody, in Subjects With RRMM
NCT03309111: Phase 1: ISB 1342, a CD38/CD3 Bispecific Antibody, in Subjects With Previously Treated Multiple Myeloma Study of ISB 1342, a...
205
Dec 6, 2017
NCT03380039: Phase 1 - Clinical Study of CAR-BCMA T Cells in Patients With RRMM
NCT03380039: Phase 1 - Clinical Study of CAR-BCMA T Cells in Patients With Refractory or Relapsed Multiple Myeloma A single arm,...
115
Dec 5, 2017
NCT03302403: Phase 1 - Clinical Study of Redirected Autologous T Cells With a CAR
NCT03302403: Phase 1 - Clinical Study of Redirected Autologous T Cells With a Chimeric Antigen Receptor in Patients With Malignant Tumors...
62
Dec 22, 2016
NCT02663518: Phase 1: A Trial of TTI-621 for Patients With Hematologic Malignancies and Solid tumors
NCT02663518: Phase 1: A Trial of TTI-621 for Patients With Hematologic Malignancies and Selected Solid Tumors NCT02663518: Phase 1: A...
39